X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-01-22 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.33 | -18,666 | 568,560 | -3% | -$99,507 | ||||||
2026-01-22 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.33 | -69,832 | 1,460,408 | -5% | -$372,267 | ||||||
2026-01-22 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.33 | -13,578 | 451,134 | -3% | -$72,383 | ||||||
| D | 2026-01-22 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $36.40 | -3,500,000 | 5,503,418 | -39% | -$127,400,000 | |||||
| M | 2026-01-21 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $41.82 | -27,845 | 33,520 | -45% | -$1,164,547 | |||||
2026-01-20 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $35.67 | -3,867 | 21,354 | -15% | -$137,936 | ||||||
| D | 2026-01-20 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale+OE | $14.31 | -75,000 | 1,021,180 | -7% | -$1,073,183 | |||||
2026-01-20 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $26.12 | -10,916 | 669,621 | -2% | -$285,071 | ||||||
2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $26.75 | -20,000 | 745,188 | -3% | -$535,099 | ||||||
2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $26.75 | -1,230 | 173,095 | -1% | -$32,902 | ||||||
| DM | 2026-01-20 | NAMS | Newamsterdam Pharma Co N.V. | Somaiya Mayur Ian | CFO | S - Sale+OE | $32.61 | -100,000 | 58,382 | -63% | -$3,260,618 | |||||
| D | 2026-01-20 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $158.93 | -10,699 | 591,315 | -2% | -$1,700,411 | |||||
2026-01-21 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $5.96 | -265 | 22,580 | -1% | -$1,579 | ||||||
| AD | 2025-12-12 | OGEN | Oragenics Inc | Telling Fred | Dir | S - Sale+OE | $0.94 | -210 | 948 | -18% | -$198 | |||||
2026-01-21 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $1.00 | +10,000 | 798,460 | +1% | +$9,975 | ||||||
2026-01-20 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $26.88 | -10,000 | 844,798 | -1% | -$268,800 | ||||||
| DM | 2026-01-20 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.04 | -4,000 | 0 | -100% | -$12,140 | |||||
| D | 2026-01-20 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale+OE | $69.74 | -1,000 | 37,793 | -3% | -$69,740 | |||||
| M | 2026-01-16 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.97 | -32,474 | 617,824 | -5% | -$161,520 | |||||
2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $82.48 | -9,514 | 97,266 | -9% | -$784,715 | ||||||
2026-01-20 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | GC | S - Sale | $2.88 | -1,689 | 384,216 | 0% | -$4,868 | ||||||
2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale | $82.48 | -34,438 | 580,505 | -6% | -$2,840,446 | ||||||
2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale | $82.48 | -8,588 | 78,077 | -10% | -$708,338 | ||||||
2026-01-21 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.23 | -13,500 | 48,752 | -22% | -$70,574 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | S - Sale | $19.79 | -1,882 | 89,324 | -2% | -$37,250 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $19.79 | -726 | 51,869 | -1% | -$14,370 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $19.79 | -1,334 | 81,724 | -2% | -$26,404 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale | $19.79 | -909 | 1,157,310 | 0% | -$17,992 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $19.79 | -8,182 | 1,627,659 | -1% | -$161,946 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $19.79 | -2,203 | 78,843 | -3% | -$43,604 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale | $19.79 | -2,892 | 164,584 | -2% | -$57,241 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $19.79 | -2,475 | 156,499 | -2% | -$48,987 | ||||||
| D | 2026-01-20 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $27.34 | -10,000 | 90,270 | -10% | -$273,420 | |||||
| D | 2026-01-20 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | CHIEF MEDICAL OFFICER | S - Sale+OE | $90.27 | -6,911 | 11,305 | -38% | -$623,853 | |||||
2026-01-21 | XCUR | Exicure, Inc. | Exicure Hitron Inc. | 10% | S - Sale | $4.50 | -258,367 | 1,598,947 | -14% | -$1,162,652 | ||||||
2026-01-16 | IMRX | Immuneering Corp | Brakewood Harold Eugene | Chief Business Officer | P - Purchase | $4.76 | +5,250 | 11,050 | +91% | +$24,990 | ||||||
| DM | 2026-01-15 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale+OE | $13.59 | -138,167 | 3,379,465 | -4% | -$1,878,094 | |||||
| DM | 2026-01-15 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale+OE | $13.59 | -138,188 | 3,379,398 | -4% | -$1,877,570 | |||||
2026-01-15 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale | $35.92 | -20,961 | 0 | -100% | -$752,833 | ||||||
| D | 2026-01-20 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $32.10 | -416 | 50,437 | -1% | -$13,354 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $75.34 | -9,933 | 42,253 | -19% | -$748,383 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale+OE | $75.59 | -9,302 | 63,890 | -13% | -$703,138 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $75.84 | -9,191 | 66,171 | -12% | -$697,045 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale+OE | $74.82 | -44,034 | 224,683 | -16% | -$3,294,624 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Kordasiewicz Holly B. | EVP, Chief Development Officer | S - Sale+OE | $75.66 | -4,141 | 14,718 | -22% | -$313,308 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | S - Sale+OE | $75.96 | -1,823 | 16,389 | -10% | -$138,475 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $75.95 | -8,353 | 26,518 | -24% | -$634,410 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $75.11 | -8,480 | 60,435 | -12% | -$636,933 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $75.15 | -8,977 | 94,757 | -9% | -$674,622 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $75.75 | -8,056 | 45,203 | -15% | -$610,276 | |||||
| D | 2026-01-20 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $18.42 | -3,760 | 50,897 | -7% | -$69,273 | |||||
2026-01-16 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -6,700 | 254,872 | -3% | -$80,431 | ||||||
2026-01-20 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $497.36 | -692 | 8,481 | -8% | -$344,173 | ||||||
2026-01-20 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale | $490.77 | -2,238 | 1,108,891 | 0% | -$1,098,343 | ||||||
2026-01-15 | NKTX | Nkarta, Inc. | Hastings Paul J | CEO | S - Sale | $2.07 | -26,046 | 390,023 | -6% | -$53,915 | ||||||
2026-01-15 | NKTX | Nkarta, Inc. | Mahmood Nadir | Pres | S - Sale | $2.07 | -5,649 | 167,727 | -3% | -$11,693 | ||||||
2026-01-16 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.52 | -20,000 | 66,418 | -23% | -$790,346 | ||||||
2026-01-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale | $18.02 | -149 | 213,992 | 0% | -$2,685 | ||||||
| D | 2026-01-15 | DVAX | Dynavax Technologies Corp | Novack David F | Pres, COO | S - Sale+OE | $15.64 | -114,000 | 63,344 | -64% | -$1,782,960 | |||||
2026-01-16 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $460.98 | -50 | 320 | -14% | -$23,049 | ||||||
2026-01-16 | ONCY | Oncolytics Biotech Inc | Seizinger Bernd R. | Dir | P - Purchase | $1.04 | +100,000 | 466,991 | +27% | +$103,770 | ||||||
2026-01-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Chief Discovery Officer | S - Sale | $28.52 | -8,000 | 154,981 | -5% | -$228,186 | ||||||
2026-01-16 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.54 | -38,782 | 2,159,860 | -2% | -$20,942 | ||||||
2026-01-16 | XCUR | Exicure, Inc. | Exicure Hitron Inc. | 10% | S - Sale | $4.50 | -734,747 | 1,857,314 | -28% | -$3,306,362 | ||||||
| A | 2025-10-17 | MYNZ | Mainz Biomed N.V. | Donahue Kevin Michael | 10% | P - Purchase | $1.51 | +685,000 | 685,000 | New | +$1,034,350 | |||||
2026-01-15 | IMRX | Immuneering Corp | Schall Thomas J. | Dir | P - Purchase | $4.67 | +21,645 | 74,530 | +41% | +$101,041 | ||||||
2026-01-14 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $29.12 | -3,489 | 854,798 | 0% | -$101,600 | ||||||
| D | 2026-01-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $31.81 | -7,000 | 1,518 | -82% | -$222,704 | |||||
| D | 2026-01-15 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | S - Sale+OE | $37.07 | -68,749 | 297,295 | -19% | -$2,548,603 | |||||
2026-01-15 | IMRX | Immuneering Corp | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | P - Purchase | $4.57 | +2,298 | 376,496 | +1% | +$10,502 | ||||||
2026-01-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $26.84 | -8,500 | 395,575 | -2% | -$228,132 | ||||||
| D | 2026-01-15 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $90.99 | -2,000 | 0 | -100% | -$181,980 | |||||
2026-01-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | P - Purchase | $1.68 | +49,000 | 2,410,477 | +2% | +$82,124 | ||||||
2026-01-14 | ACRV | Acrivon Therapeutics, Inc. | Levy Adam D. | CFO | P - Purchase | $1.70 | +8,832 | 20,983 | +73% | +$14,999 | ||||||
| E | 2025-10-17 | MYNZ | Mainz Biomed N.V. | Donahue Kevin Michael | 10% | P - Purchase | $0.62 | +643,850 | 643,850 | New | +$402,000 | |||||
| D | 2026-01-15 | ANAB | Anaptysbio, Inc | Marquet Magda | Dir | S - Sale+OE | $48.23 | -11,000 | 9,930 | -53% | -$530,531 | |||||
| M | 2026-01-13 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $5.01 | -58,289 | 650,298 | -8% | -$292,184 | |||||
| M | 2026-01-13 | OLMA | Olema Pharmaceuticals, Inc. | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL Offic | S - Sale | $28.70 | -103,822 | 139,727 | -43% | -$2,980,054 | |||||
| DM | 2026-01-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $32.66 | -19,076 | 50,437 | -27% | -$623,115 | |||||
| DM | 2026-01-13 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $40.31 | -14,134 | 61,365 | -19% | -$569,753 | |||||
| M | 2026-01-13 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.56 | -111,227 | 2,198,642 | -5% | -$61,787 | |||||
2026-01-13 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | P - Purchase | $1.72 | +10,000 | 75,308 | +15% | +$17,218 | ||||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $22.19 | -873 | 52,595 | -2% | -$19,369 | ||||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $22.19 | -1,780 | 83,058 | -2% | -$39,493 | ||||||
| D | 2026-01-15 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $469.89 | -8,300 | 36,781 | -18% | -$3,900,122 | |||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale | $22.19 | -2,277 | 1,158,219 | 0% | -$50,520 | ||||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $22.19 | -10,186 | 1,635,841 | -1% | -$225,999 | ||||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $22.19 | -2,618 | 81,046 | -3% | -$58,086 | ||||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale | $22.19 | -3,856 | 167,476 | -2% | -$85,554 | ||||||
2026-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $22.19 | -5,780 | 158,974 | -4% | -$128,242 | ||||||
| D | 2026-01-13 | BIOA | Bioage Labs, Inc. | Goldstein Dov A Md | CFO | S - Sale+OE | $19.70 | -27,000 | 22,408 | -55% | -$531,828 | |||||
2026-01-13 | BIOA | Bioage Labs, Inc. | Fortney Kristen | CEO | S - Sale | $18.12 | -233,107 | 976,949 | -19% | -$4,223,036 | ||||||
2026-01-13 | IMRX | Immuneering Corp | Neufeld Leah R | CHIEF PEOPLE OFFICER | P - Purchase | $4.15 | +2,626 | 25,970 | +11% | +$10,906 | ||||||
2026-01-13 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $29.83 | +1,800 | 5,604,102 | 0% | +$53,694 | ||||||
| DM | 2026-01-12 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV., NON-CLIN DEV OFF | S - Sale+OE | $28.25 | -110,000 | 700,438 | -14% | -$3,107,229 | |||||
| D | 2026-01-12 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $21.92 | -200,000 | 1,654,597 | -11% | -$4,384,000 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Foley Todd | Dir, 10% | P - Purchase | $18.00 | +232,870 | 4,235,403 | +6% | +$4,191,660 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.P. | 10% | P - Purchase | $18.00 | +1,112,777 | 10,260,064 | +12% | +$20,029,986 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Gadicke Ansbert | 10% | P - Purchase | $18.00 | +1,112,777 | 10,260,064 | +12% | +$20,029,986 | |||||
2026-01-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $84.33 | -500 | 74,374 | -1% | -$42,165 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |